

**This item is the archived peer-reviewed author-version of:**

Development of composite outcomes for individual patient data (IPD) meta-analysis on the effects of diet and lifestyle in pregnancy: a Delphi survey

**Reference:**

Rogozinska E., D'Amico M.I., Khan K.S., Bogaerts Annick, et al.- Development of composite outcomes for individual patient data (IPD) meta-analysis on the effects of diet and lifestyle in pregnancy: a Delphi survey

BJOG: an international journal of obstetrics and gynaecology - ISSN 1471-0528 - 123:2(2016), p. 190-198

Full text (Publishers DOI): <http://dx.doi.org/doi:10.1111/1471-0528.13764>

To cite this reference: <http://hdl.handle.net/10067/1299740151162165141>

1 **Development of composite outcomes for Individual Patient Data (IPD) meta-analysis on**  
2 **effects of diet and lifestyle in pregnancy: A Delphi survey**

3 Ewelina Rogozinska<sup>1,2</sup>, Maria I. D'Amico<sup>1</sup>, Khalid S. Khan<sup>1,2</sup>, Jose G. Cecatti<sup>3</sup>, Helena  
4 Teede<sup>4</sup>, SeonAe Yeo<sup>5</sup>, Christina A. Vinter<sup>6</sup>, Girish Rayanagoudar<sup>1</sup>, Ruben Barakat Carballo<sup>7</sup>,  
5 Maria Perales<sup>7</sup>, Jodie Dodd<sup>8</sup>, Roland Devlieger<sup>9</sup>, Annick Bogaerts<sup>9</sup>, Mireille NM van  
6 Poppel<sup>10</sup>, Lene Haakstad<sup>11</sup>, Garry X Shen<sup>12</sup>, Alexis Shub<sup>13</sup>, Riitta Luoto<sup>14</sup>, Tarja I  
7 Kinnunen<sup>15</sup>, Suzanne Phelan<sup>16</sup>, Lucilla Poston<sup>17</sup>, Tânia T Scudeller<sup>18</sup>, Nermeen El Beltagy<sup>19</sup>,  
8 Signe Nilssen Stafne<sup>20,21</sup>, Serena Tonstad<sup>22</sup>, Nina Rica Wium Geiker<sup>23</sup>, Anneloes E.  
9 Ruifrok<sup>24,25</sup>, Ben Willem Mol<sup>26</sup>, Arri Coomarasamy<sup>27</sup>, Shakila Thangaratinam<sup>1,2</sup> on behalf of  
10 the iWIP (International Weight Management in Pregnancy) Collaborative Group\*

11 <sup>1</sup>London, United Kingdom, Women's Health Research Unit, Barts and the London School of  
12 Medicine and Dentistry, Queen Mary University London

13 <sup>2</sup>London, United Kingdom, Multidisciplinary Evidence Synthesis Hub (mEsh), Barts and the  
14 London School of Medicine and Dentistry Queen Mary University London

15 <sup>3</sup>São Paulo, Brazil, Department of Obstetrics and Gynaecology, School of Medical sciences,  
16 University of Campinas (UNICAMP) Campinas

17 <sup>4</sup>Melbourne, Australia, Monash Centre for Health Research and Implementation (MCHRI),  
18 School of Public Health, Monash University

19 <sup>5</sup>North Carolina, United States of America, University of North Carolina at Chapel Hill,  
20 School of Nursing

21 <sup>6</sup>Odense, Denmark, Department of Gynaecology and Obstetrics, Odense University Hospital,  
22 Department of Obstetrics, University of Southern Denmark

23 <sup>7</sup>Facultad de Ciencias de la Actividad Física y del Deporte-INEF, Universidad Politecnica de  
24 Madrid, Madrid, Spain

25 <sup>8</sup>Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health,  
26 The University of Adelaide, Adelaide, Australia

27 <sup>9</sup>Division of Mother and Child, Department of Obstetrics and Gynaecology, University  
28 Colleges Leuven-Limburg, Hasselt and University Hospitals KU Leuven, Leuven, Belgium

29 <sup>10</sup> Department of Public and Occupational Health, EMGO+ Institute for Health and Care  
30 Research, VU University Medical Center, Amsterdam, The Netherlands

31 <sup>11</sup> Norwegian School of Sport Sciences, Department of Sports Medicine, Oslo, Norway

32 <sup>12</sup> Department of Internal Medicine, University of Manitoba, Winnipeg, Canada

33 <sup>13</sup> Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne,  
34 Australia

35 <sup>14</sup> UKK Institute for Health Promotion Research, Tampere, Finland

36 <sup>15</sup> School of Health Sciences, University of Tampere, Tampere, Finland

37 <sup>16</sup> Kinesiology Department, California Polytechnic State University, San Luis Obispo, USA

38 <sup>17</sup> Division of Women's Health, Women's Health Academic Centre, King's College London,  
39 St. Thomas' Hospital, London, United Kingdom

40 <sup>18</sup> Department of Health Sciences, Physical Therapy Course, São Paulo Federal  
41 University/Unifesp, Santos, Brazil

42 <sup>19</sup> Department of Obstetrics and Gynecology, Alexandria University, Alexandria, Egypt

43 <sup>20</sup> Department of Public Health and General Practice, Faculty of Medicine, Norwegian  
44 University of Science and Technology, Trondheim, Norway

45 <sup>21</sup> Clinical Services, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

46 <sup>22</sup> Department of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway

47 <sup>23</sup> Nutritional Research Unit, Copenhagen University Hospital Herlev, Denmark

48 <sup>24</sup> Department of Obstetrics and Gynecology, Academic Medical Centre, Amsterdam, The  
49 Netherlands

50 <sup>25</sup> Department of Obstetrics and Gynaecology, Faculty of Medicine, VU University Medical  
51 Center, Amsterdam, The Netherlands

52 <sup>26</sup> Robinson Institute, School of Paediatrics and Reproductive Health, University of Adelaide,  
53 Australia

54 <sup>27</sup> School of Clinical and Experimental Medicine, College of Medical and Dental Sciences,  
55 University of Birmingham, United Kingdom

56 \*Members of iWIP Collaborative group in the appendix

57 **Running title:** Composite for IPD synthesis on lifestyle interventions in pregnancy

58 **Author for correspondence:**

59 Ewelina Rogozinska  
60 Women's Health Research Unit  
61 Centre for Primary Care and Public Health  
62 Blizard Institute  
63 Barts and The London School of Medicine and Dentistry  
64 Queen Mary University of London  
65 Tel: +44 20 7882 5881  
66 Fax: +44 20 7882 6047  
67 Email: [e.a.rogozinska@qmul.ac.uk](mailto:e.a.rogozinska@qmul.ac.uk)  
68

69 **Objective:** To develop maternal, fetal, and neonatal composite outcomes relevant to the  
70 evaluation of diet and lifestyle interventions in pregnancy by Individual Patient Data meta-  
71 analysis.

72 **Design:** Delphi survey

73 **Setting:** The International Weight management in Pregnancy (i-WIP) Collaborative Network.

74 **Population/sample:** Twenty six researchers from the i-WIP Collaborative Network from 11  
75 countries.

76 **Methods:** A two-generational Delphi survey involving members of the International Weight  
77 management In Pregnancy (i-WIP) collaborative network (26 members, 11 countries) was  
78 undertaken to prioritise the individual outcomes for their importance to clinical care. The  
79 final components of the composite outcomes were identified using pre-specified criteria.

80 **Main outcome measures:** Composite outcomes considered to be important for the  
81 evaluation of the effect of diet and lifestyle in pregnancy.

82 **Results:** Of the 36 maternal outcomes, nine were prioritised and the following were included  
83 in the final composite: pre-eclampsia or pregnancy induced hypertension, gestational diabetes  
84 mellitus (GDM), elective or emergency caesarean section, and preterm delivery. Of the 27  
85 fetal and neonatal outcomes, nine were further evaluated, with the final composite consisting  
86 of intrauterine death, small for gestational age, large for gestational age fetus and admission  
87 to Neonatal Intensive Care Unit (NICU).

88 **Conclusion:** Our work has identified the components of maternal, fetal, and neonatal  
89 composite outcomes required for assessment of diet and lifestyle interventions in pregnancy  
90 by IPD meta-analysis.

91 **Keywords** composite outcome, Delphi survey, diet, lifestyle, maternal, fetal, neonatal

92

93

94 **Introduction**

95 Diet and lifestyle interventions in pregnancy have the potential to influence both maternal,  
96 fetal, and neonatal outcomes (1). The effectiveness of these interventions on individual  
97 outcome measures such as pre-eclampsia, gestational diabetes and preterm delivery can be  
98 assessed with high precision through large trials (2). However, evaluation of the differential  
99 effects of these interventions on relevant subgroups, such as BMI, maternal age, parity,  
100 socioeconomic status and underlying medical condition require very large sample sizes.  
101 Individual Patient Data (IPD) meta-analysis has greater power to detect any differential  
102 treatment effect across groups than aggregate meta-analysis. It can model individual risk  
103 status across participants within trials, and thus explain variability in outcomes at the patient-  
104 level (3).

105

106 Identification of the appropriate outcome (s) for evaluation of the effect of diet and lifestyle  
107 in pregnancy is challenging. More than one outcome is considered to be clinically important.  
108 Furthermore, the analysis is often limited by the low incidence of individual outcomes.  
109 Composite outcome measures (4), (5) are often chosen in primary trials to overcome the  
110 above limitations. The development of such outcomes should be based on clear pre-specified  
111 criteria with transparency in reporting. A robustly developed composite outcome measure  
112 does not exist for diet and lifestyle intervention in pregnancy.

113

114 The International Weight management in Pregnancy (i-WIP) Collaborative Network was  
115 established to assess the effects of diet and lifestyle interventions in pregnant women on  
116 maternal, fetal, and neonatal outcomes by IPD meta-analysis (6). We developed maternal,  
117 fetal and neonatal composite outcome measures for evaluation of interventions based on diet  
118 and lifestyles by IPD meta-analysis.

119

120 **Methods**

121 The initial list of outcomes was based on systematic review of literature and a previous  
122 Delphi survey (7), (8). We undertook a two-stage Delphi survey (June – Sep 2013) that was  
123 conducted in line with current recommendations (9), (10) to prioritise the maternal, fetal, and  
124 neonatal outcomes for their relevance to clinical practice. We determined a priori to consider  
125 only those outcomes that were prioritised by the Delphi panel (Appendix S2) in our  
126 development of the composite outcomes. We also decided to exclude those outcomes that  
127 were a surrogate for maternal and fetal morbidity and mortality. We developed separate  
128 composite outcomes for maternal, fetal, and neonatal complications.

129

130 *Reference panel*

131 The Delphi panel consisted of members of the i-WIP Collaborative Network, which included  
132 researchers from 11 countries who have evaluated the effect of diet and lifestyle interventions  
133 in pregnancy by randomised trials. The network is supported by World Health Organisation  
134 (WHO), and is part of the global effort in bringing together researchers, clinicians and  
135 epidemiologists (6).

136

137 *Delphi survey*

138 In the first round of the survey, the panellists were approached in person or via email, and  
139 requested to score each of the identified maternal, fetal, and neonatal outcomes for their  
140 relevance to patient care when evaluating dietary and lifestyle interventions in pregnancy. For  
141 each outcome, we provided the median and interquartile ranges (IQR) for their importance as  
142 assessed by the previous Delphi panel (7). A nine-point Likert scale was used to evaluate the  
143 importance; a score of 9 is considered to be critical, and 1 is of limited importance to patient

144 care. E-mail reminders were sent to panellists if no responses were received after 2 weeks,  
145 and the second reminder after 4 weeks.

146

147 In the first round, responders had an opportunity to add outcomes that they considered to be  
148 important, but were not provided in the questionnaire. Once all responses were received, we  
149 calculated medians and IQR for each outcome. Non-responders from the first round were not  
150 invited to a subsequent round. An IQR of  $\leq 2$  in the second round was pre-specified to  
151 indicate the consensus from the first round.

152

153 In the second round, all panellists were provided with the group scores and their individual  
154 scores for each outcome. We maintained full anonymity between the panellists, and the  
155 complete results were only known to the pollster (ER). Outcomes with a median score of over  
156 7 and an IQR indicating consensus ( $\leq 2$ ) were chosen for further evaluation for development  
157 of the composite outcomes.

158

### 159 *Development of the composite outcome*

160 The final components for inclusion in the composite outcome were based on the following  
161 criteria: considered to be critically important by the Delphi panel (score  $>7$  ), of equal  
162 importance, similar rates of occurrence, independent of each other, and evidence of same  
163 direction of the effect with the intervention.

164

## 165 **Results**

### 166 *Characteristics of the Delphi panel*

167 The Delphi panel comprised of 26 clinicians and clinical academics from 11 countries with  
168 expertise in diet and lifestyle interventions in pregnancy. This included 16 obstetricians, four

169 physiotherapists, two nutritionists, two midwives, one epidemiologist, and an endocrinology  
170 specialist. Majority of the panellists are involved in research in high income countries such as  
171 Australia (3), Belgium (2), Canada (1), Denmark (2), Finland (2), Netherlands (3), Norway  
172 (3), Spain (1), United Kingdom (5), United States (2) and two from an upper-middle income  
173 country Brazil (2) (11). Over 90% (24/26) of the panellists have experience of conducting  
174 randomised trials on diet and lifestyle interventions. Overall, the panel members have been  
175 responsible for five diet based, seven physical activity based, and 12 mixed intervention  
176 studies. Twenty six panellists ranked the maternal outcomes and 25 ranked the fetal and  
177 neonatal outcomes for their importance to patient care. Details on the rounds of the Delphi  
178 survey and development of composite outcomes are presented on the flow chart (Figure 1).

179

#### 180 *First round*

181 All panellists, (100% 26/26) completed the questionnaire consisting of 34 maternal outcomes  
182 and 27 fetal and neonatal outcomes in the initial list. Fifteen (15/34, 44%) maternal outcomes  
183 were scored as critical to patient care and 19 (19/34, 56%) outcomes were scored as  
184 important but not critical (Figure 2). The outcome threatened miscarriage was not considered  
185 to be critical to patient care (median <6).

186

187 Eleven (41% 11/27) fetal and neonatal outcomes were scored as critical to patient care and 16  
188 (59%, 16/27) outcomes were scored as important (Figure 3).

189

190 The panellists suggested consideration of pre-eclampsia and pregnancy induced hypertension  
191 to be two distinct outcomes and this was added to the list of rating in the second round.  
192 Similarly, the panel advised that elective and emergency caesarean section to be considered

193 separately, and these were added to the list for scoring in the second round.  
194 Neurodevelopment at 2 years of age and fetal cord blood (insulin or c-peptide) were added to  
195 the second round based on the recommendations of the panellists.

196

197 The individual scores showed some minimal variation ( $IQR \leq 2$ ) for twelve of the critical  
198 maternal outcomes, namely pre-eclampsia, pregnancy induced hypertension, gestational  
199 diabetes mellitus, preterm delivery, elective caesarean, emergency caesarean section,  
200 thromboembolism, admission to High Dependency Unit (HDU)/Intensive Therapy Unit  
201 (ITU), miscarriage, need for resuscitation at delivery, physical activity, and dietary  
202 behaviour. For the eleven critical fetal and neonatal outcomes there was minimal variation  
203 ( $IQR \leq 2$ ) shown in: Intrauterine death small for gestational age, large for gestational age,  
204 Admission to neonatal intensive care unit (NICU), Shoulder dystocia,  $>1$  perinatal  
205 complication, birth trauma, long term neurological sequelae, long term metabolic sequelae,  
206 hypoglycaemia, and respiratory distress syndrome.

207

### 208 *Second round*

209 Twenty-five (96%, 25/26) panellists took part in the second iteration. Eighteen (18/36, 50%)  
210 maternal outcomes had a median score of  $\geq 7$  and were considered to be critical to patient  
211 care, while 18 outcomes had a median score of  $\geq 4$  and were considered to be important.  
212 There was a narrowing of IQR for the seventeen of the outcomes showing consensus between  
213 panellists (Figure 2).

214

215 Eleven (38%, 11/29) fetal and neonatal outcomes scored between 7 and 9, and were  
216 considered to be critical to patient care. The fetal and neonatal outcomes that progressed to  
217 the second round are shown in Figure 3.

218

219 The scoring of maternal, fetal, and neonatal outcomes between the previous and the current  
220 panel was overall congruent (Appendix S1). Miscarriage, physical activity, postpartum  
221 weight retention, quality of life, and breast feeding were considered to be critically important  
222 in the current Delphi panel but only important in the previous panel. Instrumental delivery  
223 and failed instrumental delivery were critically important in previous Delphi panel but only  
224 important in this panel. Threatened miscarriage was of limited importance to patient care in  
225 the previous Delphi but considered as important by the current Delphi panel. Abnormal cord  
226 pH was critically important in the previous panel but only important in the current panel.

227

#### 228 *Components of the Composite Outcomes*

229 Nine maternal and nine fetal and neonatal outcomes with a score  $\geq 8$  were evaluated for their  
230 inclusion as components of the composite outcomes (Figure 2 and 3). The following  
231 maternal components were included: pre-eclampsia or pregnancy induced hypertension,  
232 gestational diabetes mellitus (GDM), elective or emergency caesarean section, and preterm  
233 delivery. Outcomes that occurred rarely such as thromboembolism, not well reported such as  
234 admission to HDU or ICU, or surrogate for maternal morbidity such as gestational weight  
235 gain were not included in the final list.

236

237 The following fetal and neonatal components fulfilled the selection criteria for inclusion in  
238 the composite: intrauterine death, small for gestational age fetus, large for gestational age

239 fetus, and admission to NICU. Given the long time frame required to assess the risk of long-  
240 term metabolic sequelae and neurodevelopment of the baby, they were excluded from the  
241 neonatal composite. Rare outcomes such as shoulder dystocia and birth trauma significant  
242 overlap with large for gestational age fetus, and were poorly reported, leading to their  
243 exclusion. We also excluded the outcome of more than one perinatal complication, as it was  
244 considered to be significantly dependent on the other neonatal outcomes.

245

## 246 **Discussion**

### 247 *Main findings*

248 We developed composite outcomes for evaluation of diet and lifestyle interventions in  
249 pregnancy by IPD meta-analysis. We applied robust and validated methods for this work and  
250 prioritised the outcomes through consensus involving leading multidisciplinary clinicians and  
251 researchers in the field. The detailed and transparent reporting of the process of composite  
252 outcomes development will allow researchers conducting IPD to evaluate and compare the  
253 effect of intervention on the overall composite outcomes and their individual components.

254

### 255 *Strengths*

256 To our knowledge, this is the first formally developed composite measure for evaluation of  
257 diet and lifestyle interventions during pregnancy in IPD meta-analysis. One of the major  
258 strengths of this project was the use of two iterative Delphi surveys. The second survey  
259 validated the findings of the primary panel (1) thereby increasing the reliability and  
260 reproducibility of the developed composites outcomes. The panels were fully independent  
261 and involved experts with relevant expertise. The second Delphi panel widened the area of  
262 expertise by involving researchers from wider disciplines (nutritionist, physical activity  
263 experts, midwives) and had a global reach (Canada, US, Brazil, Finland, Norway, Denmark,

264 The Netherlands, Belgium, Spain, Australia and UK). Furthermore, the majority of the  
265 panellists have experience in clinical trials in this topic. We had excellent response rate of  
266 over 90% in both rounds.

267

268 The list of maternal, fetal, and neonatal outcomes used in the survey was firstly identified  
269 through a systematic review and evaluated by the first panel (1). The Delphi panel  
270 methodology improved the panel's work and avoided counterproductive group dynamics  
271 such as domination of discussion by senior members (12). Finally, we evaluated all critically  
272 important outcomes in a systematic manner against pre-specified rigorous criteria (13) prior  
273 to their inclusion in the final composite outcomes.

274

#### 275 *Limitations*

276 The findings are based on individual and group opinions and are strongly dependant on the  
277 composition of the panel. We have minimised any resulting bias by validating the findings of  
278 one panel against a new panel of international experts in the field. Similarly, a different  
279 consensus group may have chosen other components for inclusion in the composite. The  
280 optimal size of a Delphi panel to generate consensus is not known. We decided to have a  
281 panel of moderate size, as (10-20) (14), (15) a small panel might not represent a good range  
282 of opinions on the topic, and a larger panel may lead to low response and high drop-out rates  
283 (15).

284

#### 285 *Interpretation*

286 One of the main challenges in using composite outcomes in IPD meta-analysis on diet and  
287 lifestyle interventions in pregnancy is the variation in the outcomes reported. The trials  
288 included in the i-WIP IPD meta-analysis (~~34-36~~ trials with data over ~~8000-12,000~~ women)

289 vary in the reporting of components of the composite outcomes. Some of the clinically  
290 relevant outcomes such as neurodevelopment and thromboembolism were not reported in  
291 primary studies. Similarly maternal admission to HDU or ICU was not widely reported.

292 Our decision on the final inclusion of components in the composite was a balance between  
293 rigorous and pragmatic criteria. We aimed to adhere to the pre-specified criteria as much as  
294 possible, but also refrained from including components that were not widely reported.

295 Although outcomes such as admission to NICU may be clinician driven, they are also the  
296 common outcomes uniformly reported across trials.

297

## 298 **Conclusion**

299 Any published IPD meta-analyses on diet and lifestyle interventions should provide the effect  
300 on composite outcomes and on individual outcomes. In order to maintain methodological  
301 rigour all individual components of the composites should be inspected separately during the  
302 secondary analysis (16) This will allow healthcare professionals and patients to identify  
303 whether any outcomes are disproportionately driving the findings on the composite.

304

305 The restrictions in IPD meta-analyses due to variation in outcome reporting could be reduced  
306 by two strategies. Firstly, by developing minimum core outcome sets for reporting in primary  
307 clinical trials. The COMET and the CROWN initiatives have identified the need for such  
308 core outcome sets (17), (18). Secondly, by designing prospective IPD meta-analyses with  
309 pre-specified relevant outcomes. The Global Obstetric Research Network (GONet) has  
310 prioritised this area, and has supported such a strategy for preterm research (19). Similar  
311 global initiatives are required to standardise outcome reporting for research on diet and  
312 lifestyle interventions in pregnancy.

313

314

315 **Acknowledgements**

316 We would like to acknowledge support of the Global Obstetric Network (GONet) and iWIP  
317 (International Weight Management in Pregnancy) Collaborative Group: Mireille van Poppel,  
318 Ruben Barakat Carballo, Maria Perales, Annick Bogaerts, Roland Devlieger, Jose G Cecatti,  
319 Fernanda Surita, Marcia Vitolo, Jodie Dodd, Julie Owens, Nermeen El Beltagy, Helena  
320 Teede, Cheryce Harrison, Lene Haakstad, Gary X. Shen, Alexis Shub, Narges Motahari,  
321 Janette Khoury, Serena Tonstad, Riitta Luoto, Tarja Kinnunen, Kym Guelfi, Fabio  
322 Facchinetti, Elisabetta Petrella, Suzanne Phelan, Lucilla Poston, Tânia T Scudeller, Kathrin  
323 Rauh, Hans Hauner, Kristina Renault, Linda Reme Sagedal, Ingvild Vistad, Signe Nilssen  
324 Stafne, Siv Mørkved, Kjell Åsmund Salvesen, Christina Vinter, Fionnuala McAuliffe, Arne  
325 Astrup, Nina Rica Wium Geiker, Seonae Yeo, Ben Willem Mol, Khalid S. Khan, Shakila  
326 Thangaratnam, Arri Coomarasamy, Anneloes Ruifrok, Girish Rayanagoudar, Ewelina  
327 Rogozinska

328 **Author's contribution**

329 ER performed literature search and Delphi survey questionnaire design with ST.  
330 The two-generation Delphi survey was conducted and analysed by ER. ST, KSK and JGC,  
331 HT, SY, CAV, GR, RBC, MP, JD, RD, AB, MNMP, LH, GXS, AS, RL, TIK, SP, LP, TTS,  
332 NEB, SNS, ST, NRWG, AER, BWM, AC assisted in development of the composite  
333 outcomes. ER, ST and KSK helped to formulate the question and interpret the findings. ER  
334 wrote the original draft of the paper assisted by MD and ST. ER, MD, ST, KSK, JGC, HT,  
335 SY, CAV, GR, RBC, MP, JD, RD, AB, MNMP, LH, GXS, AS, RL, TIK, SP, LP, TTS, NEB,  
336 SNS, ST, NRWG, AER, BWM, AC helped to revise the final draft.

337

338 **Declaration of interest**

339 The authors report no conflict of interest.

340 **Details of ethics approval**

341 Ethical approval was not required for this project.

342 **Funding**

343 This project is a part of the National Institute for Health Research (NIHR) HTA (Health  
344 Technology Assessment) UK programme funded study (12/01/50).

345

346 **Appendices**

347 Appendix S1. List of maternal, fetal, and neonatal outcomes considered to be relevant for  
348 studies on diet and lifestyle in pregnancy

349 Appendix S2. Maternal and fetal outcomes ranked by the previous Delphi survey of 19  
350 panelists

351 **References**

- 352 1. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW  
353 et al. Effects of interventions in pregnancy on maternal weight and obstetric  
354 outcomes: meta-analysis of randomised evidence. *BMJ*, 2012; *344*, e2088–e2088.
- 355 2. Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN et al.  
356 Antenatal lifestyle advice for women who are overweight or obese: LIMIT  
357 randomised trial. *BMJ (Clinical Research Ed.)*, 2014; *348* g1285.
- 358 3. Riley RD, Lambert PC, & Abo-Zaid G. Meta-analysis of individual participant data:  
359 rationale, conduct, and reporting. *BMJ (Clinical Research Ed.)*, 2010; *340*, c221.
- 360 4. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B et al. A  
361 Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes. *N Engl J*  
362 *Med* 2009; *361*: 1339 - 1348.
- 363 5. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS et al. Effect  
364 of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes. *N Engl J Med*  
365 2005; *352*:2477-2486
- 366 6. i-WIP (2011) [Online] Available from: <https://kamolo.org.ar/iwipid/index.asp>  
367 Accessed: 21 January 2015
- 368 7. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E et al.  
369 Interventions to reduce or prevent obesity in pregnant women: a systematic review.  
370 *Health Technol Assess* 2012; *16*, iii–iv, 1–191.
- 371 8. Thangaratinam S, & Jolly K. Obesity in pregnancy: A review of reviews on the  
372 effectiveness of interventions. *Br J Obstet Gynaecol*, 2010;*117*, 1309–1312.
- 373 9. Thangaratinam S, Ismail K, Sharp S, Coomarasamy A, O’Mahony F, Khan KS et al.  
374 Prioritisation of tests for the prediction of preeclampsia complications: a Delphi  
375 survey. *Hypertens Pregnancy*, 2007; *26*, 131–138.
- 376 10. Sinha IP, Smyth RL, & Williamson PR. Using the Delphi technique to determine  
377 which outcomes to measure in clinical trials: Recommendations for the future based  
378 on a systematic review of existing studies. *PLoS Med*, 2011; *8*(1).
- 379 11. World Bank 2014 [Online] Available  
380 from:<http://data.worldbank.org/about/country-and-lending-groups>. Accessed: 21  
381 January 2015
- 382 12. Thangaratinam S & Redman CW. The Delphi technique. *TOG* 2005; *7*(2), 120-125.
- 383 13. Montori VM, Permyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo  
384 V, Bryant D et al. Validity of composite end points in clinical trials. *BMJ*, 2005; *330*,  
385 594–596.
- 386 14. Okoli C & Pawlowski SD. The Delphi method as a research tool: an example, design  
387 considerations and applications. *Inf. Manage*, 2004; *42*(1), 15–29.
- 388 15. Hsu C, & Sandford B. The delphi technique: making sense of consensus. *Practical*  
389 *Assessment, Research & Evaluation*, 2007; *12*(10), 1–8.
- 390 16. Pogue J, Devereaux P J, Thabane L, & Yusuf S. Designing and analyzing clinical  
391 trials with composite outcomes: Consideration of possible treatment differences  
392 between the individual outcomes. *PLoS ONE*, 2012; *7*(4).

- 393 17. COMET initiative (2015) [Online] Available from: <http://www.comet-initiative.org/>  
394 Accessed: 21 January 2015
- 395 18. Khan KS. The CROWN initiative: Journal editors invite researchers to develop core  
396 outcomes in women's health. *J Gynecol Obstet Biol Reprod (Paris)* 2014; vol. 43, (9)  
397 637-639.
- 398 19. GONet [Online] Available from: <http://www.globalobstetricsnetwork.org/> Accessed:  
399 23 Jan 2015

400

## 401 **Figures**

402 Figure 1. Flow chart of outcome selection in the Delphi survey of prioritisation of maternal,  
403 fetal, and neonatal outcomes relevant to patient care with diet and lifestyle interventions in  
404 pregnancy

405 Figure 2. Prioritisation of maternal outcomes relevant to clinical care of mothers on diet and  
406 lifestyle interventions

407 Figure 3. Prioritisation of fetal and neonatal outcomes relevant to clinical care of mothers on  
408 diet and lifestyle interventions

409